Cap-dependent endonuclease inhibitors (CENis) - NHRC

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAVSUP FLT LOG CTR NORFOLK

Contract Value

Not provided

Codes & Classification
Solicitation Number

N0018926QB059

NAICS

541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Classification Code

AN42

Additional Details
Set Aside

NONE

Place of Performance

Galveston, Texas, UNITED STATES

SourceSAM
Documents4
The Department of the Navy, through the Naval Supply Systems Command Fleet Logistics Center Norfolk (NAVSUP FLT LOG CTR NORFOLK), has issued a combined synopsis/solicitation for the preclinical development of Cap-dependent endonuclease inhibitors (CENis). This procurement seeks to advance CENis—a class of small molecule compounds—as broad-spectrum antiviral therapeutics, with a particular focus on viruses necessitating biosafety level 4 (BSL-4) containment. The initiative is designed to support the Naval Medical Research Command located at Fort Detrick, Maryland, with the primary place of performance specified as Galveston, Texas. The scope of work encompasses all activities required to select lead CENi candidates. This includes conducting both in vitro and in vivo efficacy studies, as well as the characterization and optimization of lead compounds. The contractor will be expected to provide comprehensive research support expertise in the preclinical development of these inhibitors, ensuring that all work aligns with the stringent requirements associated with BSL-4 pathogens. The period of performance for this effort is 36 months, allowing for a thorough and iterative process of candidate selection, testing, and optimization. Key objectives of this procurement include: - Identification and selection of promising CENi lead compounds. - Execution of efficacy studies in both laboratory (in vitro) and animal (in vivo) models. - Detailed characterization and optimization of lead candidates to enhance their therapeutic potential. - Provision of specialized research support for work involving high-containment (BSL-4) viruses. The opportunity is classified under NAICS code 541715, which pertains to Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology), and carries the Product Service Code AN42. There are no set-aside restrictions associated with this solicitation, making it open to all qualified entities. The contracting activity is managed by NAVSUP FLT LOG CTR NORFOLK, a federal office under the Department of Defense and the Department of the Navy. Interested parties may direct inquiries to the primary contact, Brian Kinkade ([email protected], 771-229-2412), or the secondary contact, Jacob Gephart ([email protected], 771-229-2712). The solicitation was posted on May 26, 2026, with responses due by May 28, 2026. Additional details, including attachments, can be accessed via the official SAM.gov opportunity listing (Opportunity ID: 9c47ad00291343ad8b22f15cf93fe208). This procurement represents a significant opportunity for organizations with expertise in antiviral drug development, high-containment laboratory research, and preclinical therapeutic evaluation. Contractors should be prepared to demonstrate capabilities in handling BSL-4 agents, conducting rigorous efficacy studies, and advancing small molecule therapeutics from lead identification through preclinical optimization.